ArticleCureus2025
Bridging the Gap: First Clinical Experience With Linear Accelerator (LINAC) Radiosurgery Using Automated HyperARC for Brain Metastasis in a Low-Resource Setting in Pakistan.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Brain metastasis is becoming increasingly common in cancer patients. Over the past decade, stereotactic radiosurgery (SRS) and fractionated stereotactic radiotherapy (fSRT) have become the cornerstone of treatment for limited brain metastases. Sophisticated linear accelerator (LINAC)-based HyperArc volumetric modulated arc therapy (HA-VMAT) systems offer the unique advantage of high-precision radiotherapy. The purpose of this study is to present our first clinical experience with the HA-VMAT planning approach for brain metastases treated at our hospital. Methods This retrospective study included 72 patients with 1-5 brain metastases treated at our institution with SRS/SRT using HA-VMAT. A dosimetric evaluation of clinical characteristics and outcomes was carried out. Results From April 2020 until June 2021, a total of 86 brain metastases in 72 patients were treated. The median age was 45 (range 18-75). The most common histology was breast cancer (n = 48 (66.7%)). Sixty-two (86.1%) patients had a single brain metastasis. Thirty-two (44%) patients were treated with single-fraction SRS, while 40 (65%) received fSRT. The radiobiological equivalent dose in 2 Gy fractions (EQD2) ranged from 50.4 to 81.6 Gy for SRS and from 37.25 to 60.0 Gy for fSRT. The median GTV and PTV volumes for a single fraction were 1.98 cc (range 0.13-13.3) and 4.49 cc (range 0.64-21.20), respectively. The mean PTV was 10.96 cc (range 2.25-34) and 19.04 cc (4.40-75.88). Complete response was observed in 12.5% of the patients. The median follow-up was 17 months (range 1-38 months). The progression-free survival at 1 year was 54.6%. Only one patient developed radiation necrosis. Conclusion Brain metastases can be safely and effectively treated with SRS/fSRT using HA-VMAT, which decreases the likelihood of local complications and improves local control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.